CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities:
Net Loss	$ (32,125,858)	$ (25,921,284)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization	650,142	514,362
Stock-based Compensation	4,387,554	7,174,596
Research and Development - Licenses Acquired (Related Party)	1,100,000
Increase in Inventory Reserves	8,784,000
Loss on Disposal of Assets	4,752	10,777
Realized Loss on Sale of Investments Available-for-Sale	222,338	792,207
Foreign Currency Translation Adjustment	(10,762)	1,306
Changes in Assets and Liabilities:
Increase in Insurance Receivable	(371,217)
Increase in Accounts Receivable	(623,948)	(962,338)
Decrease in Inventory	(835,641)	343,490
(Increase) Decrease in Other Assets	(165,712)	264,975
Increase (Decrease) in Accounts Payable	269,912	(1,636,840)
Increase in Settlement Payable	416,668
Increase in Other Liabilities	271,889	634,238
Decrease in Deferred License Revenue	(2,394,051)	(2,328,418)
Changes in Assets and Liabilities	(3,432,100)	(3,684,893)
Cash Used In Operating Activities	(20,419,934)	(21,112,929)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale	(20,178,127)	(35,733,677)
Sale of Investments Available-for-Sale	33,895,481	51,918,745
Purchase of Equipment	(744,256)	(1,682,913)
Purchase of Research and Development Licenses (Related Party)	(250,000)
Proceeds on Sale of Assets	400	725
Cash Provided By Investing Activities	12,723,498	14,502,880
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Shares	22,000,000	123,603
Common Share Issuance Costs	(64,049)
Proceeds from the Exercise of Employee Stock Options, Net of Tax	67,548
Repurchase of Common Shares to Pay Employee Withholding Taxes		(2,287,231)
Cash Provided By (Used In) Financing Activities	22,003,499	(2,163,628)
Increase (Decrease) In Cash and Cash Equivalents	14,307,063	(8,773,677)
Cash At Beginning Of Period	8,406,917	17,180,594
Cash At End Of Period	22,713,980	8,406,917
Supplemental Cash Flow Information:
Change in Unrealized Gain on Marketable Securities Available-for-Sale	109,293	$ 866,031
Research and Development Licenses (Related Party)	$ 850,000